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Lung cancer is one of the leading causes of cancer-related deaths in the United States. A
major hurdle for improved therapies is immune suppression mediated by the tumor and
its microenvironment. The lung tumor microenvironment (TME) contains large numbers of
tumor-associated macrophages (TAMs), which suppress the adaptive immune response,
increase neo-vascularization of the tumor, and provide pro-tumor factors to promote
tumor growth. CD11b is highly expressed on myeloid cells, including TAMs, where it
forms a heterodimeric integrin receptor with CD18 (known as CD11b/CD18, Mac-1,
CR3, and αMβ2), and plays an important role in recruitment and biological functions
of these cells, and is a validated therapeutic target. Here, we describe our pre-clinical
studies targeting CD11b in the context of lung cancer, using pharmacologic and genetic
approaches that work via positive allosteric modulation of CD11b function. GB1275
is a novel small molecule modulator of CD11b that is currently in Phase 1/2 clinical
development. We assess GB1275 treatment effects on tumor growth and immune
infiltrates in the murine Lewis Lung Carcinoma (LLC) syngeneic tumor model. Additionally,
as an orthogonal approach to determine mechanisms of action, we utilize our recently
developed novel CD11b knock-in (KI) mouse that constitutively expresses CD11b
containing an activating isoleucine to glycine substitution at residue 332 in the ligand
binding CD11b A-domain (I332G) that acts as a positive allosteric modulator of CD11b
activity. We report that pharmacologic modulation of CD11b with GB1275 significantly
reduces LLC tumor growth. CD11b KI mice similarly show significant reduction in both
the size and rate of LLC tumor growth, as compared toWTmice, mimicking our observed
treatment effects with GB1275. Tumor profiling revealed a significant reduction in TAM
infiltration in GB1275-treated and in CD11b KI mice, increase in the ratio of M1/M2-like
TAMs, and concomitant increase in cytotoxic T cells. The profiling also showed a
significant decrease in CCL2 levels and a concomitant reduction in Ly6Chi monocytes
in circulation in both groups. These findings suggest that positive allosteric modulation
of CD11b reduces TAM density and reprograms them to enhance the adaptive immune
response and is a novel therapeutic strategy against lung cancer.
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INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths
worldwide and accounts for more deaths than breast, prostate,
and colon cancers combined (1). Conventional treatments
against lung cancer are not very effective, partly due to
tumor heterogeneity and its complex mutational landscape
(2). Recent advances utilizing immune checkpoint inhibitors
have made a significant impact on reducing tumor growth
and metastases and have resulted in significantly improved
survival of lung cancer patients (3, 4). However, these
agents show efficacy in only a subset of patients and
are associated with significant adverse events (5). Thus,
there is an urgent need for improved therapeutics against
lung cancer.
Tumor-associatedmacrophages (TAMs) play a significant role
in suppressing the immune response against cancer and alter
patient outcomes, depending on their abundance and activity (6–
9). TAMs augment cancer immune escape by multiple means,
including providing growth factors for tumor survival, increasing
neoangiogenesis, suppressing T cell influx and T cell-mediated
immunity, and influencing chemokine signaling and extracellular
matrix (ECM) integrity to enhance tumor cell extravasation
and metastasis (10–15). TAMs represent one of the most
abundant leukocyte populations in the tumor microenvironment
(TME) and, for most cancer types, are associated with poor
survival (16–20). Thus, there are increasing efforts targeting
these cells toward developing new therapies against cancer
[reviewed in Ruffell and Coussens (7) and Mantovani et al.
(8)]. These targeted therapies include both inhibiting recruitment
of new TAMs and manipulating the polarization state of
resident macrophages.
Although macrophages exist across a continuum of
polarization states (9, 21, 22) for simplicity they are often
categorized into two major types—M1 and M2 (23, 24).
M1 macrophages are considered to be pro-inflammatory
and anti-tumor, whereas M2 macrophages are considered
to be anti-inflammatory and pro-tumor (9). Indeed, a high
abundance of M2 macrophages [for example, CD204+ TAMs
(25)] in the TME is often associated with poor clinical
outcomes in patients, while an increase in M1 macrophage
(for example, HLA-DR+ TAMs) abundance in tumors often
correlates with better prognosis for lung cancer patients
(26, 27).
TAMs rely on chemokine cues and cell adhesion molecules for
trafficking to the TME, including highly expressed heterodimeric
integrin receptors, such as α4β1 and CD11b/CD18 (also known
asMac-1, CR3, and αMβ2) (20, 28–30). The integrin heterodimer
CD11b/CD18 is highly expressed on myeloid cells and plays
an important role in cell adhesion, migration to inflammatory
sites, and phagocytosis (31). It also modulates pro- and anti-
inflammatory signaling in cells (32). Thus, CD11b/CD18 is an
ideal receptor for targeting TAMs as a means by which tumor
growth can be controlled. However, many previous approaches
for targeting this family of integrins, especially using antagonists
or inhibitors of ligand binding have not been clinically very
successful (33). Additionally, we recently found that global
deletion of CD11b in mice (CD11b−/−) results in increased
tumor volume compared to that of wild type (WT) animals and
produces a significantly increased tumor burden, suggesting that
CD11b plays an important role in controlling tumor growth (34).
This also suggests a need for alternate strategies targeting CD11b.
Toward this, we recently developed novel small molecule
modulators of CD11b (30, 34, 35). Counter-intuitively, these
modulators reduce leukocyte cell migration and tissue
recruitment by increasing CD11b-dependent cell adhesion
in vivo (36). These compounds bind to the ligand-binding
domain of CD11b [known as CD11b A- or I-domain (31)
CD11bA]. Specifically, they bind an allosteric pocket of CD11bA,
thus, positively modulating the domain (and the integrin) into
its ligand-competent conformation (35). As such these serve
as positive allosteric modulators of CD11b, and ultimately
suppress myeloid cell recruitment into inflamed tissues, thereby
reducing injury (32, 35). Additionally, we recently showed that
the orally bioavailable CD11b positive allosteric modulator,
GB1275 [previously known as ADH-503 (30)] significantly
reduces growth of pancreatic tumors in multiple mouse models
and improves survival (30). However, efficacy of this oral
agent has not been described in lung cancer. Here, we present
our studies with this agent in a murine lung cancer model.
Importantly, in order to complement our pharmacologic
approaches of modulating CD11b, we also recently developed
a novel CD11b knock-in (KI) mouse that globally incorporates
the point mutation, I332G, in the allosteric pocket, which
modulates a CD11bA conformational change (34, 37). This
mutation allosterically renders CD11bA (and the integrin)
ligand competent, in much the same way as GB1275, thereby
providing us with a unique tool by which we further validate our
mechanism of action in a murine lung cancer model. Together,
this study demonstrates a novel approach to treating lung cancer
via positive modulation of CD11b.
MATERIALS AND METHODS
Animal Models
Lewis lung carcinoma (LLC) cells were purchased from ATCC.
For each experiment, LLC cells were thawed and passaged at least
three times before inoculating into mice. Cells were routinely
checked and found negative formycoplasma using theMycoAlert
assay (Lonza). Eight to ten week old C57BL/6 wildtype (WT)
mice utilized in these experiments were obtained from The
Jackson Laboratory. Both male and female mice were used. We
have previously described our CD11b (I332G) knock-in (KI)
mouse model, backcrossed onto the C57BL/6 background (34).
To establish LLC tumors in mice, we subcutaneously inoculated
1.0 × 106 cells in 100 µL cold phosphate-buffered saline (PBS)
into the mouse rear flank, for accessible continuous tumor
monitoring. Tumors became palpable (>0.5 cm) 5–7 days after
inoculation. Mice with palpable tumors were randomized into
groups and some mice were treated. Mice were euthanized at
the described endpoints or when a tumor measured 2 cm in any
diameter (38). The Institutional Animal Care andUse Committee
(IACUC) at Rush University Medical Center approved all
animal studies.
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Treatments
GB1275 [previously known as ADH-503 (30)] was used at
a dose of 60 mg/kg in all tumor studies. A GB1275 stock
was prepared in a vehicle solution of 0.5% Methylcellulose
(Calbiochem) and 0.02% Tween-80 (Sigma) in water. Control
animals were administered the vehicle alone. GB2175 or the
vehicle was administered to animals twice daily by oral gavage
(o.g.). For T cell depletion, CD4- and CD8-depleting antibodies
(anti-mCD4 clone GK1.5 and anti-mCD8 clone 2.43, BioXCell)
were administered via intraperitoneal (i.p.) injection every 3–
4 days, with the first injection at 500 µg of antibody/animal
before tumor implantation and subsequent injections at 250 µg
of antibody/animal (39). CCR2i (PF-04136309, Pfizer) was used
for the in vitromigration assay at 20 nM.
Mouse Tissue Harvesting and Flow
Cytometry
Mice were anesthetized using Ketamine/Xylazine before blood
collection was performed via orbital venous puncture. Collected
blood was allowed to clot at room temperature for 2 h before
centrifugation (at 5,000 RPM for 5min) to collect sera for
analyses. Sera were stored at −80◦C until analyses. Tumor
tissues were manually dissected, minced, and digested in 10mL
Hank’s Balanced Salt Solution (HBSS) containing 0.5 mg/mL
Collagenase IV, 0.1 mg/mL Hyaluronidase V, 0.6 U/mL Dispase
II, and 100U/mLDNase I, for 30min at 37◦Cwith gentle shaking.
The digestion was stopped by adding 10mL PBS containing 0.5%
bovine serum albumin (BSA) and 2mM EDTA. Tumor tissues
were then filtered through a 70µmnylon mesh and subsequently
red blood cells (RBC) were lysed by incubating with RBC lysis
buffer containing ammonium chloride for 5min (Biolegend).
Single-cell suspensions were stained for flow cytometry analysis
with fluorophore-conjugated anti-mouse antibodies at dilutions
following manufacturer recommendations. Data were acquired
using an LSR-Fortessa flow cytometer and analyzed using FlowJo
software version 10.2. Gating strategies were designed according
to previously published studies (30, 34). All antibodies used for
flow cytometry analysis are listed in Supplementary Table 1.
Human NSCLC Tissue
Human tissues were obtained from surgically resected specimens
from NSCLC patients diagnosed in the Department of Pathology
at Rush University Medical Center and accessed via the
Rush University Biorepository Core. Patients from whom
these tissues were obtained were positive for end-stage
disease and did not receive neoadjuvant therapy. Tissues
were embedded in paraffin blocks and processed into 7µm
sections for immunohistochemistry (IHC) staining. All tissues
were collected under informed consent and access to the
biorepository was approved by the Institutional Review
Board (IRB) at Rush University Medical Center under study
protocol #17060903-IRB02.
The TCGA NSCLC overall survival data (TCGA LUAD)
was analyzed using Kaplan–Meier Plotter survival analysis
software (http://kmplot.com/analysis/) (40). CD11b (ITGAM—
probe 205785_at) expression was categorized at the top- and
the bottom-third terciles (67th and 33rd percentile) and patient
subpopulations were designated as CD11b-high and CD11b-
low based on these cutoffs. Survival outcome in CD11b-
high vs. CD11b-low patient subpopulations was examined
using Kaplan–Meier log-rank test and the univariate Cox
proportional hazards regression analysis prebuilt in the K–M
plotter. For determining the correlation between CD11b and
CCL2 expression in patient samples, the TCGA gene expression
data on LungAdenocarcinoma (LUAD) patients was retrieved via
the FireBrowse tool from the Broad Institute. Data was confined
to patient diseased tissue, and all normal human tissue samples
were removed, leaving 125 patient samples. CD11b and CCL2
expression data were both log2 transformed to assess for fold-
change in expression. Excel version 14.7.7 was used to calculate
Pearson correlations between these log2-transformed data.
Histology
Tissues were fixed in 10% formalin overnight while shaking.
Tissues were then dehydrated in increasing grades of ethanol
and xylene, embedded in paraffin, and cut into 7-µm sections.
All IHC on human samples was performed at the University of
Illinois at Chicago Histology Core using an BONDRx automated
immunostainer (Leica), and slides were scanned using an Aperio
AT2 scanner (Leica). A rabbit monoclonal anti-human CD11b
antibody (clone EP1345Y, Abcam) was used for IHC staining
of CD11b. Tissues were quantified with Aperio ImageScope
software (Leica) using an algorithm in HALO software (Indica
Labs) to detect positive cells among total cells per tissue, after
negative panning of necrotic or tissue-folded areas.
Bone Marrow-Derived Macrophage Culture
Bonemarrow cells were aseptically harvested from 8- to 10-week-
old mice, as previously described (41). Bone marrow-derived
macrophages (BMDMs) were obtained by differentiating the
harvested cells in Dulbecco’s Modified Eagle Medium (DMEM)
containing 20% FBS and 1% penicillin/streptomycin (PS) and
50 ng/mL M-CSF for 7 days (41). Tumor-conditioned media
(TCM) was collected from LLC supernatants after 2 days of
growth. After subculture, LLC cells were allowed to grow for
24 h and serum-starved for another 24 h before the supernatant
was collected. Serum-starved LLC TCM was centrifuged (1,200
RPM for 5min) and filtered (0.22µm) before freezing. After
differentiation, BMDMs were stimulated with thawed LLC
TCM for 4 h with or without GB1275 at a final concentration
of 20 µM.
qRT-PCR
Total RNA was isolated from cells and tissue using the
Qiazol kit (Qiagen), as per manufacturer instructions, and kept
frozen at −80◦C until extraction. Total mRNA was extracted
using the RNeasy kit (Qiagen), according to manufacturer
protocols. cDNA synthesis was performed on 1 µg total
RNA using the iScript reverse transcriptase kit (Biorad).
Quantitative PCR was performed using commercially available
mouse primers for Gapdh, Arg1, Il10, Tgfb, Ccl2, Il1b, Il12b,
Cxcl9, and Ifna using Quantitect primer assays (Qiagen). SYBR
Green 2X Master Mix was used for qPCR analysis (Biorad).
mRNA levels were normalized to Gapdh levels (dCt = Ct
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FIGURE 1 | Human lung cancer tissues have a dense CD11b+ myeloid population. (A) Representative images of human NSCLC and normal lung tissues assessed
for CD11b+ cells at 2X and 20X magnifications. Red box in 2X micrographs indicates region magnified at 20X. Red arrows in 20X images indicate CD11b+ cells.
Lung tissue sections (7µM) were stained by IHC using BONDRx automated system (Leica). (B) Slides were scanned using Aperio AT2 systems (Leica) and analyzed
for total CD11b+ cells over total tissue area (2µm), reported as CD11b+ density. Slides were negative panned for necrotic or tissue folded areas before
quantification. (n = 10 per group, p = 0.0142). Statistical analysis by Mann-Whitney t-test. (C) Kaplan–Meier (KM) overall survival (OS) curves of NSCLC patient
datasets from TCGA, GEO, and caBIG stratified according to expression of CD11b (ITGAM) categorized at the top and bottom thirds, resulting in 242 patients in
CD11b-low and 243 patients in CD11b-high group. P-value of the log-rank test is shown in the graph. Data presented using K–M plotter (40).
target gene – Ct Gapdh) and reported as relative mRNA
expression [2(−ddCt) where ddCt = dCt experimental – dCt
control] (Qiagen).
Migration Assay and ELISA
The THP-1 human monocyte cell line was obtained from ATCC
and tested negative for mycoplasma. CCR2i (PF-04136309)
was obtained from MedChem Express. Monocytes were pre-
treated with GB1275 (20µM), CCR2i (20 nM), or vehicle
control for 30min prior to seeding (0.5 × 106 cells per
well) in the upper chambers of a 24-well transwell plate
(Corning, 8µm). The bottom chambers were filled with
media containing either vehicle, CCL2 (50 ng/mL), or TCM.
Monocytes that transmigrated to the bottom wells after 6 h
were collected and counted using an automated cell counter
(ViCellXR). Percent migration was calculated as: (cells migrated
in the bottom chamber)/(total cells seeded in the upper
chamber)× 100.
LLC tumor tissue was snap frozen in liquid nitrogen
and stored at −80◦C. Tumor tissue was weighed and lysed
by sonication in RIPA lysis buffer containing protease
inhibitor (2.5 µL per 1mg of tissue). Tissue lysis occurred
for 30min on ice before samples were centrifuged (13,000
RPM for 15min at 4◦C). The lysate was collected and
protein concentration was determined by BCA assay. CCL2
protein was detected by ELISA (R&D systems) following the
manufacturer’s protocol.
Statistics
Statistical analyses were performed using Prism 8.2 software
(GraphPad Software). Two-tailed student’s t-test (two groups)
and ANOVA (multiple groups) were utilized when the data
were normally distributed. Mann-Whitney test was used for
comparison between two groups when data was not normally
distributed. Animals were randomly assigned to groups prior
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FIGURE 2 | CD11b modulation effectively slows LLC tumor progression and is dependent on T-cell mediated anti-tumor immunity. (A) Study design schematic
describing the LLC model and treatment regimen of GB1275. (B) Wildtype LLC tumor-bearing mice were treated with Vehicle or GB1275. Tumor growth measured as
tumor volume are shown (n = 7–10 per group). Tumor volume was measured with calipers. (C) Endpoint (Day 18) tumor weights are shown from mice treated with
Vehicle or GB1275 (n = 7–10 per group). (D) Transgenic CD11b KI or WT mice were inoculated with LLC and tumor growth was observed over time. Tumor growth
measured in tumor volume are shown (n = 7–10 per group). (E) Endpoint (Day 18) tumor weights are shown from WT or CD11b KI mice (n = 7–10 per group).
P-values as stated on graphs. Statistical analysis by Mann-Whitney t-test.
to beginning treatment. All experiments were replicated
2–4 times.
RESULTS
CD11b+ Cells Are Abundant in Human
Non-Small Cell Lung Cancer (NSCLC)
To examine relative abundance of CD11b+ myeloid cells
in human lung cancer, we compared the density of these
cells in human NSCLC vs. normal lung tissue sections by
IHC. Clinical characteristics of these samples are described in
Supplementary Figure 1. NSCLC tissues showed a significantly
higher density of CD11b+ leukocytes in the tumor as compared
to the normal tissue sections (Figures 1A,B). Additionally, we
analyzed the data on lung adenocarcinoma (LUAD) from The
Cancer Genome Atlas (TCGA) (42), to determine if CD11b
expression in TME correlated with clinical outcomes. Expression
levels of CD11b across the LUAD patient groups were categorized
at the top and bottom thirds and Kaplan–Meier survival curves
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FIGURE 3 | Pharmacologic CD11b modulation alters innate immune responses in the lung tumor microenvironment. (A) Quantification of tumor-infiltrating myeloid
cells including CD11b+ cells, (B) F4/80+ macrophages, (C) Ly6G+ granulocytes, (D) Ly6C+ monocytes, (E) “M1” macrophages (CD11b+F4/80+MHCII+), (F) “M2”
macrophages (CD11b+F4/80+CD206+), (G) CD103+ conventional dendritic cells (cDC1s) and (H) CD11b+ cDC2s from LLC tumor tissues treated with Vehicle or
(Continued)
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FIGURE 3 | GB1275 after 10 days treatment (n = 5–10 per group). Populations gated under live single cell CD45+ cells. Gating strategies are shown in
Supplementary Figure 1. (I) Immunofluorescence (IF) histologic representative images of LLC tumor tissue probing for F4/80 and CD206 in Vehicle or GB1275
treatment groups. (J) Quantification IF images in I showing percent colocalization of F4/80+CD206+ macrophages in LLC tumors. (K) Same as in panel (I), but
showing IF staining on LLC tumor tissues probing for F4/80 and MHCII colocalization. (L) Same as in panel (J) but, for quantification of IF images in panel (K).
P-values as stated in graphs. Statistical analysis by Mann-Whitney t-test.
were plotted from CD11b-high and CD11b-low groups, with
242 patients in CD11b-low and 243 patients in CD11b-high
groups. Our analysis showed that higher CD11b expression is
significantly linked with patients with lower survival rate in
LUAD (Figure 1C), with median survival of 103 months in the
CD11b-low group and 59 months in CD11b-high group. These
results are not too surprising, given the recent studies showing
presence of a high level of neutrophils and macrophages in
the lung TME, providing it with its unique immune contexture
(43–45). Collectively, these data suggest that CD11b+ cells are
increased in the lung TME. Furthermore, CD11b may provide
prognostic value and could serve as a potential target for
NSCLC therapy.
Positive CD11b Modulation via
Pharmacologic and Genetic Approaches
Slows Lung Cancer Tumor Progression
To study whether CD11b modulation affects tumor growth
and can be a novel therapeutic approach, we utilized the
murine LLC transplantable lung cancer model using syngeneic
immunocompetent C57BL/6 mice (38) (Figure 2A). First, we
applied a pharmacologic approach by administering CD11b
modulator GB1275 to LLC tumor-bearing mice. Our recent
studies have shown that global deletion of CD11b (CD11b−/−)
results in significantly larger tumors in mice, partly due
to increase in immunosuppressive TAMs in the TME (34),
suggesting that active CD11b may have an important role in
controlling tumor growth. Here, we found that treatment of
wild type C57BL/6 mice (WT) with GB1275 significantly reduces
tumor growth, as compared to animals treated with vehicle
alone (Figure 2B). Measurement of tumor weight at the end of
the experiment also showed a significant lower tumor weight
in GB1275-treated animals as compared to vehicle controls
(Figure 2C). These data suggest that pharmacologic modulation
of CD11b activity results in significant reduction in lung tumor
growth in mice.
Next, to confirm that CD11b modulation was indeed the
mechanism by which GB1275 reduced LLC tumor growth, we
utilized our newly developed CD11b knock-in (KI) mouse (34)
in these experiments. The CD11b KI mouse globally expresses
constitutively active CD11b [via a knocked-in I332G substitution
(34, 37)], mimicking the CD11b modulation caused by GB1275
treatment. We observed that, upon subcutaneous injection of
LLC cells, CD11b KI mice showed a significant reduction in
tumor growth, slower tumor growth, and significantly reduced
tumor weight at the endpoint as compared to WT mice
(Figures 2D,E). Overall, the tumor burden in the CD11b KI
resembles the lower tumor burden observed in mice treated
with CD11bmodulator GB1275. Collectively, these data establish
that positive allosteric modulation of CD11b, via orthogonal
pharmacologic and genetic approaches reduces growth of lung
tumor in mice.
Positive CD11b Modulation Slows Tumor
Progression by Changing Immune Cell
Populations Within the TME
Next, we sought to further explore how CD11b modulation
slows lung cancer progression. We have previously shown that
GB1275 does not reduce viability of tumor or immune cells
(34), but rather transmigration and recruitment of CD11b+
cells into TME from circulation (32, 35). To fully explore the
nature of immune cell changes in the TME, we quantified
the various cells of the immune cell compartment in tumors
using flow cytometry. We found that GB1275 treatment
results in significant reduction in CD11b+ cells in isolated
tumors, as compared to vehicle-treated mice (Figure 3A).
Flow cytometry analyses also showed a significant reduction
in F4/80+ macrophages (Figure 3B), granulocytes (Figure 3C
and Supplementary Figure 1A) and monocytes (Figure 3D and
Supplementary Figure 1B) in the TME, further suggesting that
pharmacologic modulation of CD11b with GB1275 reduces
transmigration and recruitment of CD11b+ cells into the lung
TME. To further evaluate the effect of pharmacologic CD11b
modulation on recruitment of myeloid cells into tumors, we
conducted an in vitro monocyte migration assay using LLC
tumor conditioned media (TCM) (Supplementary Figure 2A).
We observed that control myeloid cell chemoattractant CCL2 as
well as LLC TCM both elicit strong transmigration of human
THP-1 monocytes. GB1275 significantly inhibits monocyte
transmigration, comparable in efficacy to CCR2 inhibition
(CCR2i) (Supplementary Figure 2B). These results confirm
that in vivo effects of GB1275 are likely partly mediated
via an effect on transmigration of CD11b+ cells into the
TME. M2 polarized TAMs are associated with lung tumor
growth, whereas M1 macrophages reduce tumor growth (25,
26). To examine if GB1275 treatment changes the level of
these macrophage sub-types, we utilized polarization-specific
markers in flow cytometry, and found that GB1275 significantly
increases the frequency of M1 macrophages (F4/80+MHCII+)
and significantly decreases the frequency of M2 macrophages
(F4/80+CD206+) within the TME (Figures 3E,F). Moreover, we
found that GB1275 significantly decreases type-2 conventional
CD11b+ dendritic cells (cDC2) and significantly increases type-1
CD103+ dendritic cells (cDC1), suggesting an increase in antigen
cross-presentation to CD8+ T cells after CD11b modulation
(Figures 3G,H and Supplementary Figure 1C), suggesting that
the in vivo effects of GB1275 on lung cancer are partly
also mediated via increasing the ratio of M1/M2 polarized
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FIGURE 4 | Genetic CD11b modulation alters innate immune responses in the lung tumor microenvironment. (A) Quantification of tumor-infiltrating myeloid cells
including CD11b+ cells, (B) F4/80+ macrophages, (C) Ly6G+ granulocytes, (D) Ly6C+ monocytes, (E) “M1” macrophages (CD11b+F4/80+MHCII+), (F) “M2”
macrophages (CD11b+F4/80+CD206+), (G) CD103+ conventional dendritic cells (cDC1s), and (H) CD11b+ cDC2s from LLC tumor tissues in WT or CD11b KI
animals 10 days treatment (n = 5–10 per group). Populations gated under live single cell CD45+ cells. Gating strategies are shown in Supplementary Figure 1. (I)
(Continued)
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FIGURE 4 | Immunofluorescence (IF) histologic representative images of LLC tumor tissue probing for F4/80 and CD206 in WT or CD11b KI groups. (J) Quantification
IF images in panel (I) showing percent colocalization of F4/80+CD206+ macrophages in LLC tumors. (K) Same as in panel (I), but showing IF staining on LLC tumor
tissues probing for F4/80 and MHCII colocalization. (L) Same as in panel (J) but, for quantification of IF images in panel (K). P-values as stated in graphs. Statistical
analysis by Mann-Whitney t-test.
FIGURE 5 | Pharmacologic CD11b modulation alters adaptive immune responses in the lung tumor microenvironment. (A) Quantification of tumor-infiltrating T cells
including CD8+ cytotoxic lymphocytes (CTLs), (B) Ki67+ CD8+ T cells, (C) FoxP3+ regulatory T cells (Tregs), and (D) CD4+ T cells from LLC tumor tissues treated
with Vehicle or GB1275 after 10 days of treatment (n = 5–10 per group). (E) Immunofluorescence (IF) histologic representative images of LLC tumor tissue probing for
CD8 or CD4 in Vehicle or GB1275 treatment groups. (F,G) Quantification of CD8 and CD4 IF images in panel (E), respectively. Statistical analysis by Mann-Whitney
t-test.
macrophages in the TME, confirming similar findings in
pancreatic cancer models (30). To further validate these findings,
we analyzed tumors using immunofluorescence (IF), which
similarly showed a significant decrease in F4/80+CD206+ M2-
type macrophages (Figures 3I,J) as well as a significant increase
in F4/80+MHCII+ M1-type macrophages (Figures 3K,L) in LLC
tumors treated with GB1275 as compared to the vehicle controls.
To determine if this mechanism is cellular independent of
the way CD11b is functionally modulated, we also analyzed
isolated tumors from the LLC tumor bearing CD11b KI
mice. Flow cytometry based analyses of the tumors replicated
the findings from above (Figures 4A–H) and showed that,
as compared to the LLC tumors from WT mice, tumors
from the KI mice show significant decrease in CD11b+
cells, F4/80+ cells, monocytes, and granulocytes, and M2
macrophages, and a significant increase in M1 macrophages.
The results also show a significant decrease in CD11b+
cDC2s and a significant increase in CD103+ cDC1s, further
confirming that positive modulation of CD11b is highly
effective in controlling lung tumor growth in vivo. Furthermore,
immunofluorescence-based analyses of the tumor tissues also
showed a significant decrease in F4/80+CD206+ M2-polarized
macrophages (Figures 4I,J) as well as a significant increase in
F4/80+MHCII+ M1-polarized macrophages (Figures 4K,L) in
LLC tumors from CD11b KI mice, as compared to tumors from
the WT animals.
Analyses of the T cell compartment in GB1275-treated
tumors showed a coincident increase in the frequency of Ki67+
(proliferating) CD8+ T lymphocytes in the TME. GB1275
treatment also led to an increase in CD4+ T cells and
a concomitant decrease in CD4+FoxP3+ regulatory T cells
(Tregs) (Figures 5A–D and Supplementary Figures 1D,E). IF
staining further confirmed a significant increase in number of
CD8+ T lymphocytes in GB1275-treated tumors as compared
to vehicle controls. IF showed no significant difference
between CD4+ cells between the two groups (Figures 5E–G).
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FIGURE 6 | Genetic CD11b modulation alters adaptive immune responses in the lung tumor microenvironment. (A) Quantification of tumor-infiltrating T cells including
CD8+ cytotoxic lymphocytes (CTLs), (B) Ki67+ CD8+ T cells, (C) FoxP3+ regulatory T cells (Tregs), and (D) CD4+ T cells from LLC tumor tissues treated with
Vehicle or GB1275 after 10 days of treatment (n = 5–10 per group). (E) Immunofluorescence (IF) histologic representative images of LLC tumor tissue probing for CD8
or CD4 in WT or CD11b KI groups. (F,G) Quantification of CD8 and CD4 IF images in panel (E), respectively. Statistical analysis by Mann-Whitney t-test.
FIGURE 7 | The effects of pharmacologic CD11b modulation are T cell-dependent. (A) T cells were depleted from mice using anti-CD4 and anti-CD8 depleting
antibodies (BioXCell) and treated GB1275. Tumor growth measured in tumor volume are shown (n = 7–10 per group). Tumor volume was measured with calipers.
(B) Endpoint (Day 12) tumor weights are shown from groups in F (n = 5–8 per group). P-values as stated on graphs. Statistical analysis by Mann-Whitney t-test.
We also similarly analyzed the tumors from CD11b WT
and KI mice and found a similar pattern of changes in
T cell populations by flow cytometry (Figures 6A–D) and
IF (Figures 6E–G).
These results suggest that CD11b modulation via
pharmacologic and genetic approaches similarly changes
the immune phenotype within the TME to augment anti-tumor
immune responses and suggests that T cell mediated
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FIGURE 8 | CD11b modulation changes macrophage gene expression to enhance anti-tumor immunity. (A) Relative mRNA expression analysis of BMDMs treated
with LLC TCM or TCM+GB1275 (20µM) for 4 h in media containing M-CSF. Changes in gene expression are reported as relative mRNA expression from TCM (n =
3–6). (B) Q-PCR mRNA expression analysis of BMDMs from WT or CD11b KI mice treated with LLC TCM for 4 h in media containing M-CSF. Changes in gene
expression are reported as relative mRNA expression from WT TCM (n = 3–6). *P < 0.05, **P < 0.01. Statistical analysis by student’s t-test.
immunity may be partly responsible for controlling tumor
growth. To confirm the role of T cells in controlling tumor
growth in this model, we depleted CD4+ and CD8+ T
cells in tumor-bearing mice using an established protocol
(39) (Supplementary Figures 3A,B). We found that, in
this context, removal of T cells results in loss of GB1275
efficacy (Figures 7A,B). Taken together, these results suggest
that CD11b modulation elicits its efficacy in controlling
lung tumor growth partly by reducing TAM frequency
in tumors and partly by increasing the ratio of M1/M2
macrophages, that results in induction of T cell-mediated
anti-tumor immunity.
Positive Modulation of CD11b Polarizes
Macrophages Toward an M1 Phenotype
Our in vivo results suggested a role for CD11b-dependent
macrophage polarization. Thus, to further examine the changes
in macrophage polarization in TME as a result of CD11b
modulation, we stimulated primary bone marrow derived
macrophages (BMDMs) with LLC tumor-conditioned media
(TCM) in the presence or absence of GB1275. We found
significant changes in expression level of genes involved in
classical (M1) and alternative (M2) activation of macrophages
in as a result of CD11b-modulation in the presence of
LLC TCM. When stimulated with TCM, GB1275-treated
macrophages showed significantly lower expression of M2
genes, including Arg1, Il10, Tgfb, and Ccl2 compared to
TCM treatment alone (Figure 8A). Simultaneously, GB1275-
treated macrophages showed an increased level of M1 genes,
including Il1b, Il12b, Cxcl9, and, Ifna compared to TCM
treatment alone. TCM stimulation of CD11b KI BMDMs also
showed similar gene expression pattern, as compared to WT
cells (Figure 8B), confirming that CD11b modulation results
in increased M1-polarized macrophages in the presence of
LLC TCM.
Positive CD11b Modulation Reduces
CCL2-Mediated Monocyte Recruitment
The chemokine CCL2 recruits myeloid cells to the TME in
vivo and is primarily secreted by lung cancer cells and myeloid
cells in the TME (46). Increased CCL2 levels result in a feed
forward loop, leading to increased CCR2-mediated TAM cell
recruitment (36, 47). Circulating levels of CCL2 also increase
in lung cancer patients and correlate with poor survival (48).
Neutralizing CCL2, or its receptor CCR2, reduces tumor growth
and metastases (47, 48). We examined CCL2 levels in sera of
control mice using ELISA and found that they were significantly
increased in LLC tumor-bearing animals compared to non-
tumor-bearing animals, confirming published reports (36, 46,
47). Analysis of tumor tissue lysates as well as sera from LLC
tumor-bearing mice treated with GB1275 showed a significant
reduction in circulating CCL2 levels, compared to vehicle-
treated controls (Figures 9A,B). Similarly, tumor tissue lysates
and sera from LLC tumor-bearing KI mice also showed a
significant reduction in circulating CCL2 levels, compared to
WT controls (Figures 9C,D). Finally, we observed a strong
correlation between CCL2 and CD11b expression from the
human TCGA lung adenocarcinoma dataset (Figure 9E). These
data suggest that reduced TAM recruitment in the TME, upon
pharmacologic and genetic allosteric modulation of CD11b, also
results in reduced CCL2 secretion, likely leading to a blocked
feed-forward loop in myeloid cell recruitment to the TME.
CCL2 in circulation recruits Ly6Chi monocytes from the
bone marrow and into the TME, where these cells differentiate
into TAMs and typically play a pro-tumoral role (43). Since
we observed reduction in CCL2 levels in both the tumor and
sera of CD11b-modulated tumors (i.e., GB1275 treated and
CD11b KI), we hypothesized that reduced CCL2 in the blood
may result in reduced levels of circulating Ly6Chi monocytes.
Peripheral blood from vehicle-treated or GB1275-treated tumor-
bearingmice was collected and stained for circulatingmonocytes.
In line with our hypothesis, there was a significant decrease
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FIGURE 9 | CD11b modulation reduces tumor secreted and circulating CCL2 levels in tumor-bearing mice. (A) Levels of CCL2 protein concentration from tumor
tissue lysates of healthy controls (no tumor) or endpoint Control (C)- or GB1275 (GB)-treated mice (tumor-bearing) measured by ELISA (n = 4–5). (B) Levels of CCL2
measured from peripheral blood of non-tumor bearing (No Tumor), or tumor bearing (Tumor) animals (n = 4–8) in Vehicle or GB1275 treated animals. (C) Same as in
panel (A), but from healthy controls (no tumor) or endpoint WT or CD11b KI mice (tumor-bearing) measured by ELISA (n = 4–5). (D) Same as in panel (B), but in WT
or CD11b KI animals. P-values as stated in the graphs. Statistical analysis by Mann-Whitney t-test. (E) Pearson correlation analysis comparing the fold change in
CD11b expression levels to the fold change in CCL2 expression levels in Lung Adenocarcinoma samples.
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FIGURE 10 | CD11b modulation reduces Ly6Chi inflammatory monocytes in circulation and increases Ly6Clo patrolling monocytes. (A) Frequencies of
CD11b+Ly6G−Ly6Chi circulating monocytes of CD45+ cells in Vehicle or GB1275 treated mice (n = 8) either from non-tumor bearing (No Tumor) or tumor-bearing
(Tumor) mouse peripheral blood. (B) Same as in panel (A), but showing frequencies for WT vs. CD11b KI animals (n = 5). (C,D) Same as in panel (A,B) respectively,
but showing CD11b+Ly6G−Ly6Clo monocyte frequencies in peripheral blood (n = 5–8).
in circulating CD11b+Ly6G−Ly6Chi classical monocytes in
both GB1275-treated and CD11b KI tumor bearing mice
(Figures 10A,B). Concomitantly, there was a significant increase
in Ly6Clo (CD11b+Ly6G−Ly6Clo) monocytes in circulation
in both the GB1275-treated and CD11b KI tumor-bearing
mice (Figures 10C,D). Increased Ly6Clo and decreased Ly6Chi
circulating monocytes suggest more patrolling of endothelium
and less systemic inflammatory burden induced by CD11b
modulation, which is likely also a contributing factor in
how positive modulation of CD11b results in reduced tumor
growth in vivo.
Overall, the above data suggests the following working
model of how modulation of CD11b activity regulates tumor
growth (Figure 11); Lung tumors, via upregulation of CCL2,
recruit Ly6ChiCD11b+ myeloid cells, which get polarized to
an M2- like state in the TME, resulting in increased M2/M1
TAM ratio in the TME in a feed-forward loop. As a result,
there is increased T cell immune suppression in the TME,
promoting lung tumor growth. However, positive allosteric
modulation of CD11b activity suppresses this feed forward loop
by decreasing CCL2 levels, reducing Ly6ChiCD11b+ myeloid
cells in circulation and reduced recruitment of these myeloid
cells in TME (and thus reduced M2 TAM density in the
TME), which leads to increased M1/M2 TAM ratio, increased
CD8+ T cell infiltration, ultimately resulting in significantly
suppressed lung tumor growth. Future studies will probe these
mechanisms further.
DISCUSSION
Targeting tumor-associated myeloid cells has the potential to
overcome the limitations of existing immunotherapies for cancer
patients (30, 49–53). Increased TAMdensity in tumors, especially
CD204+ M2-like TAMs (25), correlates with poor patient
prognosis in multiple cancer types, including lung cancer, while
HLA-DR+ M1-like TAMs correlate with better prognosis for
patients (26). These results suggest that an approach that involves
a combination of decreasing TAM density and reducing the
ratio of M2/M1-like TAMs in TME may be an exciting new
therapeutic strategy to treat lung cancer. Our results presented
here offer one such approach. Integrin CD11b is highly expressed
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FIGURE 11 | Schematic diagram showing our current working model. (A) Normal lung tumor growth secretes high levels of CCL2 to attract CD11b+Ly6Chi
monocytes into circulation, wherefrom these cells are increasingly recruited to the TME and converted into M2 tumor associated macrophages (TAMs). As a result, a
feed-forward loop is established that results in suppression of CD8+ T cells in the TME and promoting lung tumorigenesis. (B) Positive allosteric modulation of CD11b
reduces recruitment of CD11b+Ly6Chi monocytes and, thus, M2-polarized TAM density, reduces CCL2 levels, resulting in suppression of the feed-forward loop. This
leads to increased density of tumor-suppressing CD8+ T cells in the TME and suppression of lung tumor growth.
on TAMs. We determined that CD11b+ cells are abundant in
human NSCLC samples. Allosteric activation of CD11b using
two orthogonal approaches, pharmacologic (using GB1275) and
genetic (using a I332G CD11b knock-in), provides significant
reductions in the recruitment of F4/80+ TAMs in the TME and,
concomitantly, results in significant decrease in tumor burden
in LLC murine models, which is consistent with our previous
results in other model systems (32, 34, 35). Furthermore, we
observed an accompanying increase in Ki67+CD8+ T cells
and decrease in FoxP3+ regulatory T cells in the TME. These
data indicated that CD11b-dependent modulation of TAMs
resulted in an increased adaptive immune response, which
might be the effectors for controlling tumor growth. Indeed,
depletion of all T-cells in GB1275-treated LLC tumor bearing
mice showed tumor growth similar to the vehicle treated animals,
confirming that T cells are the effector cells controlling tumor
growth in this model system. Additionally, we found increased
CD103+ dendritic cells in the treated animals, which suggests
enhanced antigen cross-presentation, likely further enhancing T
cell-mediated anti-tumor immunity (15). Collectively, our data
highlight positive allosteric modulation of CD11b as a novel
strategy for targeting TAM cell recruitment and polarization in
TME to enhance both the innate and adaptive immune responses
against lung cancer.
Additionally, our findings that CD11b modulation
suppresses circulating CCL2 levels in tumor-bearing mice
may be an important contributing mechanism defining how
CD11b modulation slows tumor growth. Several studies have
reported tumor-promoting properties of CCL2 in accelerating
metastasis, increasing angiogenesis, and recruiting immune
suppressive macrophages to the tumor (47, 54–56). Indeed,
lung adenocarcinoma patients with higher levels of CCL2
progress faster and have worse prognosis (48). Additionally,
blocking CCL2, or its receptor CCR2, reduces tumor growth and
metastases, and this mechanism is currently being target in the
clinic (47, 48). Data presented here provides a novel approach
to limit CCL2/CCR2 mechanism in solid tumors, perhaps
circumventing some of the limitations with the CCL2/CCR2
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targeting therapeutics currently under development (55). Future
work investigating the link between CD11b modulation and
CCL2 signaling will further inform clinical translation of
these studies.
In summary, the data presented here show that integrin
CD11b is a clinically relevant target in lung cancer, with high
abundance seen in NSCLC patient tumors and high CD11b
expression correlated with worse overall survival for lung cancer.
Our data also show that positive allosteric modulation of CD11b
alters both the myeloid cell infiltration and TAM phenotype and
functions within the TME to decrease lung cancer burden in
vivo. A combination of pharmacologic and genetic approaches
suggests that these in vivo effects are a direct result of CD11b
modulation. Thus, positive allosteric modulation of CD11b
augments the anti-tumor immune response and is a novel
therapeutic strategy against lung cancer.
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Supplementary Figure 1 | Representative gating strategies for flow cytometry
analysis of tumors. (A) Flow diagram representing the beginning gating strategy
for all tumor cell flow cytometry analysis. All cells were first gated into single cells
using side scatter height by area and then side scatter width by area. Under single
cells, live CD45+ cells were gated. Under this gating strategy all subsequent
immune cell populations were analyzed. (B) Myeloid cell gating strategy starting
with gating strategy in panel (A), followed by CD11b+ –> Ly6G –> Ly6C –>
F4/80+, and then M1 and M2 macrophages were analyzed as F4/80+MHCII+
and F4/80+CD206+, respectively. Ly6G+ cells are granulocytes and Ly6C+ cells
are monocytes. Isotype controls for F4/80, CD206, and MHCII were used to
inform gate drawing. (C) Dendritic cell (DC) gating strategy, starting with flow in
panel (A), followed by Ly6C –> CD11c+MHCII+ –> CD24+F4/80–, and further
followed by gating of CD11b+ cDCs or CD103+ DCs. (D) CD4T cell gating,
starting with flow in panel (A), followed by CD3+ –> CD4+ –> FoxP3+ cells.
Isotype control for FoxP3 was used to inform gate drawing. (E) CD8T cell gating,
starting with flow in panel (A), followed by CD3+ –> CD8+ –> Ki67+ cells.
Isotype control was used for Ki67 to inform gate drawing. Flow diagrams are
representative of gating strategy used in all stained tumor samples.
Supplementary Figure 2 | (A) Schematic diagram describing the monocyte
migration assay. (B) Migration assay analysis of THP1 human monocytes treated
with media (–), 20 nM CCR2i (PF-4136309) or 20µM GB1275. Pre-treated or
untreated THP1 monocytes (5 × 105) were seeded in the upper chamber and
then submerged in media (–), 50 ng/mL CCL2, or tumor conditioned media (TCM)
reported as % migration = cells counted in bottom chamber out of total cells
seeded in upper chamber. ∗P < 0.05. Statistical analysis by Mann-Whitney t-test.
Supplementary Figure 3 | Successful in vivo depletion of CD4 and CD8T cell in
LLC tumor-bearing mice. (A) Representative flow cytometry analysis of tumor cells
from vehicle or anti-CD4/CD8 antibody depleted mice. (B) Representative flow
cytometry analysis of peripheral blood cells from vehicle or anti-CD4/CD8
antibody depleted mice. Gated under live single cell, CD45+CD3+ cells.
Supplementary Table 1 | Clinical characteristics of human lung adenocarcinoma
tissues stained for CD11b in Figures 1A,B. Normal tissue acquiesced from the
Northwestern University biorepository was either cadaveric or designated
“non-tumor” normal tissue by pathology report.
Supplementary Table 2 | List of antibodies used for flow cytometry analysis.
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